Stockfacts
Use CasesDocsPricing
Log inSign up free
OverviewFinancialsTrendsTranscriptsOptionsInstitutionsInsidersCorporate ActionsSEC Filings
Stockfacts

EOD US-equity data for investors and AI agents

Data is end-of-day, not real-time, and not investment advice

Use CasesDashboard

DMAAR

Drugs Made In America Acquisition Corp.

CIK 0002028614 · Nasdaq

NasdaqFinancialsBlank Checks
$0.10
↑ 0.00 (0.00%)
as of Jul 10, 2026
End-of-day close, not real-time intraday
Live price (Google Finance) ↗
Overall read: BearishOverall score · based on 2/4 lenses
FundamentalsOwnershipTechnicalsOptions

Risks: Fundamentals, Technicals; Excluded: Ownership, Options (no data)

Key stats

Market Cap
$2.55M
P/E Ratio
0.38
EPS
Not covered
Dividend Yield
Not covered
52W Position
32%
Beta
0.52

Valuation multiples

Fwd P/E
Not covered
PEG
Not covered
P/B
-0.35
P/S
Not covered
EV/Revenue
Not covered
ROE
-90.2%
Valuation data covers 8,503/9,463 US-listed stocks (89.9%).

Price · 1Y

251 trading days

End-of-day close, not real-time intraday

52-Week RangePosition 32%
$0.04$0.24

Latest Financials

2025-12-31 FY
Revenue
–
Net Income
$5.94M
Total Assets
$239.92M
Free Cash Flow
–

Recent news